NCT07944690
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX49 in Advanced/Metastatic Solid Tumors
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Secondary (9)
Show 4 moreShow less
Arms and interventions
Patients with advanced/metastatic solid tumors, who are refractory to standard treatment or for which no standard treatment is available.
Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars.
Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars.
Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars.
Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars.
Drugs: HLX49, Trastuzumab Deruxtecan for Injection (T-DXd)
Sites
2 sites in 2 countries
Australia 1, China 1